Literature DB >> 1382137

Sub-chronic exposure to opiates in the rat: effects on brain levels of substance P and calcitonin gene-related peptide during dependence and withdrawal.

G K Tiong1, T L Pierce, J E Olley.   

Abstract

Substance P (SP) and calcitonin gene-related peptide (CGRP) are putative transmitters in the central and peripheral (sensory) nervous systems. In this study, we examined the effects of dependence on and withdrawal from morphine and methadone on brain SP and CGRP content. Female Long Evans rats (70-100 g) were provided with plain drinking water or solutions containing opiate. No choice of drinking fluid was allowed. The maintenance level of each opiate (0.8 and 0.4 mg/ml for morphine and methadone, respectively) was continued for 4 days. Following an injection with naloxone (10 mg/kg i.p.) or saline, animals were decapitated 0, 20, or 60 min later and regional brain peptide content was measured by specific radioimmunoassays. SP and CGRP content in opiate-maintained and naive animals were similar following saline injection. However, following naloxone injection in morphine-maintained animals, SP content was elevated in the hypothalamus and midbrain at 20 min, but by 60 min was no longer distinguishable from basal (0 min) level. CGRP content was increased in the medulla oblongata and followed a comparable time course but, unlike SP, was not altered in the hypothalamus or midbrain. No alterations were observed in methadone-maintained animals. These results correlated with the peak of the behavioral morphine withdrawal syndrome and were consistent with the comparatively milder abstinence encountered in methadone medication.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382137     DOI: 10.1002/jnr.490320412

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  8 in total

Review 1.  The mechanism of μ-opioid receptor (MOR)-TRPV1 crosstalk in TRPV1 activation involves morphine anti-nociception, tolerance and dependence.

Authors:  Yanju Bao; Yebo Gao; Liping Yang; Xiangying Kong; Jing Yu; Wei Hou; Baojin Hua
Journal:  Channels (Austin)       Date:  2015-07-15       Impact factor: 2.581

2.  Chronic morphine drinking establishes morphine tolerance, but not addiction in Wistar rats.

Authors:  Ralf Binsack; Ming-lan Zheng; Zhan-sai Zhang; Liu Yang; Yong-ping Zhu
Journal:  J Zhejiang Univ Sci B       Date:  2006-11       Impact factor: 3.066

3.  Extracellular signal-regulated kinase 5 in the cerebrospinal fluid-contacting nucleus contributes to morphine physical dependence in rats.

Authors:  Chun-Guang Wang; Yan-Ling Ding; Tian-Fang Zheng; Jing-Qiu Wei; He Liu; Yu-Feng Chen; Jia-You Wang; Li-Cai Zhang
Journal:  J Mol Neurosci       Date:  2012-11-11       Impact factor: 3.444

4.  The role of spinal neuropeptides and prostaglandins in opioid physical dependence.

Authors:  Tuan Trang; Maaja Sutak; Remi Quirion; Khem Jhamandas
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

5.  Spinal administration of lipoxygenase inhibitors suppresses behavioural and neurochemical manifestations of naloxone-precipitated opioid withdrawal.

Authors:  Tuan Trang; Maaja Sutak; Remi Quirion; Khem Jhamandas
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

6.  An in vitro model of morphine withdrawal manifests the enhancing effect on human immunodeficiency virus infection of human T lymphocytes through the induction of substance P.

Authors:  Xu Wang; Steven D Douglas; Jin-Song Peng; Dun-Jin Zhou; Qi Wan; Wen-Zhe Ho
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

7.  Responses of limbic and extrapyramidal substance P systems to nicotine treatment.

Authors:  Mario E Alburges; Paul S Frankel; Amanda J Hoonakker; Glen R Hanson
Journal:  Psychopharmacology (Berl)       Date:  2008-09-05       Impact factor: 4.530

8.  Remifentanil discontinuation and subsequent intensive care unit-acquired infection: a cohort study.

Authors:  Saad Nseir; Jérémy Hoel; Guillaume Grailles; Aude Soury-Lavergne; Christophe Di Pompeo; Daniel Mathieu; Alain Durocher
Journal:  Crit Care       Date:  2009-04-21       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.